BioStock: Respiratorius' H1 marked by positive patent decision and secured financing
Respiratorius' half-year report for 2024 highlights the positive decision from the Patent Trial and Appeal Board regarding the company's US patent application for the formulation of VAL001. Additionally, Respiratorius has secured capital through a rights issue expected to ensure the company’s operations for the next two years. The company now has continued hopes of finding a partner for VAL001.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se